Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 12, 2016. The document serves as a transaction notification regarding a specific insider trading event rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide aggregate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It solely reports on a specific share acquisition transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of ordinary shares under ShareReward Plan |
| Instrument | Ordinary shares of 25 pence each (ISIN: GB0009252882) |
| Share Price | £16.7127 |
| Total Volume | 14 Ordinary shares (7 partnership shares + 7 matching shares) |
| Transaction Date | July 11, 2016 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
The filing does not contain comparative financial data or material changes to the company's financial position versus prior periods. It reports a routine equity compensation transaction.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of a transaction by a Person Discharging Managerial Responsibilities (PDMR).
Key Facts for Investor Verification
- Insider Identity: The transaction was executed by Mr. R G Connor, President of Global Manufacturing & Supply.
- Transaction Nature: The acquisition was made under the Company's ShareReward Plan, involving both partnership and matching shares.
- Market Price: The shares were acquired at £16.7127 per share on the London Stock Exchange.
- Volume: The total number of shares acquired in this specific notification was 14.